替雷利珠单抗联合贝伐珠单抗治疗不可切除晚期肝癌的临床研究

Clinical Study of Tirellizumab Combined with Bevacizumab in the Treatment of Unresectable Advanced Liver Cancer

目的:探讨替雷利珠单抗联合贝伐珠单抗在不可切除晚期肝癌患者中的临床效果。方法:选择2021年7月—2023年1月阳江市人民医院肿瘤一科收治的96例不可切除晚期肝癌患者作为研究对象,根据随机数表法分为两组,各48例。对照组口服索拉菲尼治疗,观察组给予替雷利珠单抗联合贝伐珠单抗静脉滴注治疗。比较两组近期疗效、生化指标[甲胎蛋白(AFP)、铁蛋白、γ-谷氨酰转肽酶(GGT)]及毒副反应发生率。结果:治疗3个月后,观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组生化指标比较,差异无统计学意义(P>0.05);治疗3个月后,两组AFP、铁蛋白及GGT水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组用药期间腹痛、骨髓抑制、恶心呕吐、白细胞下降等毒副反应总发生率比较,差异无统计学意义(P>0.05)。结论:替雷利珠单抗联合贝伐珠单抗用于不可切除晚期肝癌患者中,能获得较高的近期疗效,改善AFP、铁蛋白及GGT水平,未增加毒副反应发生率。

Objective:To investigate the clinical effect of Tirellizumab combined with Bevacizumab in patients with unresectable advanced liver cancer.Method:A total of 96 patients with unresectable advanced liver cancer admitted to the Department of Oncology of Yangjiang People's Hospital from July 2021 to January 2023 were selected as the study objects,and they were divided into two groups by random number table method,with 48 cases in each group.The control group was treated with oral Sorafenib,and the observation group was treated with intravenous infusion of Tirellizumab combined with Bevacizumab.The short-term efficacy,biochemical indexes[alphafetoprotein(AFP),ferritin,gamma-glutamyl transferase(GGT)]and incidence of toxic and side effects were compared between the two groups.Result:After 3 months of treatment,the total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in biochemical indexes between the two groups(P>0.05).After 3 months of treatment,the levels of AFP,ferritin and GGT in the two groups were lower than those before treatment,and the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of toxic and side effects such as abdominal pain,myelosuppression,nausea and vomiting,and white blood cell decline between the two groups(P>0.05).Conclusion:Tirellizumab combined with Bevacizumab in patients with unresectable advanced liver cancer can achieve high short-term efficacy,improve the levels of AFP,ferritin and GGT,and do not increase the incidence of toxic and side effects.